Valeant Comments On Endo Offer To Buy Salix

(RTTNews) - Valeant Pharmaceuticals International, Inc. (VRX, VRX.TO) issued statement in response to Endo International PLC's (ENDP, ENL.TO) unsolicited offer to acquire Salix Pharmaceuticals, Ltd. (SLXP).

"We are firmly committed to our all-cash agreed transaction, which delivers immediate and certain value to Salix shareholders. The tender offer is scheduled to expire at the end of the day on March 31, 2015, and Valeant expects to be in the position to close the transaction on April 1, 2015," Valeant said.

Earlier today, Endo said it offered to buy Salix (SLXP) for $175 per share in cash and stock, or $11 billion, superior to Valeant's offer in February to buy Salix for $158 per share in cash.